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to human CYP2D6 established in CYP2D6 mice, but not in 
wild-type mice. CYP2D6-specific T cells reacted to human 
CYP2D6 peptides with intermediate homology to the mouse 
homologues, but not to those with high homology, indicat-
ing that molecular mimicry rather than molecular identity 
breaks tolerance and subsequently causes severe persistent 
autoimmune liver damage. The CYP2D6 model provides a 
platform to investigate mechanisms involved in the immu-
nopathogenesis of autoimmune-mediated chronic hepatic 
injury and evaluate possible ways of therapeutic interfer-
ence.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 The etiology of autoimmune hepatitis (AIH) is poorly 
understood, although the major autoantigen, cytochrome 
P450 2D6 (CYP2D6), has been identified and immuno-
dominant epitopes mapped. One reason might be the lack 
of an appropriate animal model that reflects the patho-
genic processes occurring in patients suffering from AIH. 
Experimental hepatitis was often reported to be only 
transient and many current models for autoimmune liver 
disease depend on a rather complex disease induction 
protocol (for review, see  [1] and  [2] ). 
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 Abstract 
 Cytochrome P450 2D6 (CYP2D6) has been identified as the 
major autoantigen in type 2 autoimmune hepatitis (AIH). 
However, because of a lack of appropriate animal models, 
the etiology of AIH is still poorly understood. We generated 
a mouse model for AIH using the human CYP2D6 as a trig-
gering molecule for autoimmunity. We infected wild-type 
FVB mice with an adenovirus expressing human CYP2D6 
(Ad-2D6) to break self-tolerance to the mouse CYP2D6 ho-
mologues. Ad-2D6-infected mice showed persistent fea-
tures of liver damage including hepatic fibrosis, cellular infil-
trations, focal-to-confluent necrosis and generation of anti-
CYP2D6 antibodies, which predominantly recognized the 
identical immunodominant epitope recognized by LKM-1 
antibodies from AIH patients. Interestingly, Ad-2D6 infec-
tion of transgenic mice expressing the human CYP2D6
(CYP2D6 mice) resulted in delayed kinetics and reduced se-
verity of liver damage. However, the quantity and quality
of anti-CYP2D6 antibodies was only moderately reduced in 
CYP2D6 mice. In contrast, the frequency of CYP2D6-specific 
CD4 and CD8 T cells was dramatically decreased in CYP2D6 
mice, indicating the presence of a strong T cell tolerance
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 Therefore, we generated a mouse model for human 
AIH using the natural human autoantigen CYP2D6 as a 
triggering molecule for initiation of an autoimmune pro-
cess. CYP2D6 has been identified as the major autoanti-
gen recognized by liver-kidney microsomal antibodies 1 
(LKM-1) in type 2 AIH at the end of the 1980s  [3, 4] . Since 
then, many autoreactive epitopes have been identified on 
the B cell  [5–10] as well as T cell level  [11–13] . The immu-
nodominant epitope DPAQPPRD is recognized by LKM-
1 antibodies of the majority of type 2 AIH patients  [8, 10, 
14, 15] . The three-dimensional structure of CYP2D6 re-
veals that the immunodominant as well as most of the 
subdominant epitopes are located at the surface of the 
molecule and are therefore easily accessible by patient 
LKM-1 antibodies  [9, 16] . 
 Interestingly, an amino acid sequence homology
has been documented between DPAQPPRD of human 
CYP2D6 and the infected cell protein 4 of herpes sim-
plex virus 1  [8] , indicating the existence of molecular 
mimicry between the major autoantigen in type 2 AIH 
and a human pathogen. However, no association of her-
pes simplex virus 1 infection and type 2 AIH could be 
demonstrated to date. 
 The novel CYP2D6 mouse model is based on the con-
cept of molecular mimicry as a potential mechanism for 
the initiation and/or acceleration of autoimmunity. The 
molecular mimicry concept  [17–19] first requires an in-
fection by a pathogen which shares a structural related-
ness with components of the host in order to cause an 
aggressive immune response with the goal of eliminating 
the invading pathogen as fast as possible. Second, the ac-
tivated antipathogen immune reactivity is then directed 
against host structures that share a structural similarity 
to the pathogen, resulting in autoimmunity. Several as-
sociations between pathogen infections and human auto-
immune diseases have been made in the past  [20, 21] . 
However, definite proof for molecular mimicry being re-
sponsible for autoimmune diseases is rare. One of the few 
examples of postinfectious autoimmunity due to molecu-
lar mimicry was demonstrated for the Guillain-Barré 
syndrome, where an association of infection with  Cam-
pylobacter jejuni sharing a structural homology of the li-
po-oligosaccharide with the peripheral nerve GM1 gan-
glioside could be convincingly reproduced in an animal 
model  [22] . In addition, convincing evidence has been es-
tablished for  Streptococcus pyogenes -induced acute rheu-
matic fever, where the lysoganglioside of the host shares 
a structural similarity with  N -acetyl-  - D -glucosamine, 
the dominant epitope of the group A streptococcal car-
bohydrate  [23] . For autoimmune liver disease, it has been 
recently demonstrated that environmental factors, such 
as the bacterium  Novosphingobium aromaticivorans and 
chemical xenobiotics, confer molecular mimicry to the 
immunodominant structure in the major autoantigen in 
primary biliary cirrhosis PDC-E2 containing the pros-
thetic group lipoic acid  [24, 25] . Among chemical xeno-
biotics, the cosmetic and food additive 2-octynoic acid 
shows a high structural similarity to lipoic acid, and in-
jection of 2-octynoic acid coupled to bovine serum albu-
min (BSA) resulted in the generation of primary biliary 
cirrhosis-like disease in wild-type C57BL/6 mice  [26] .
 Several animal models have been generated that used 
virus infections paired with a transgenic expression of 
target antigens. In many cases the target antigen was 
identical to the triggering antigen. For example in the 
RIP-LCMV mouse model for type 1 diabetes (T1D), the 
glycoprotein (GP) or the nucleoprotein (NP) of the lym-
phocytic choriomeningitis virus (LCMV) was expressed 
in transgenic RIP-LCMV mice under the control of the 
rat-insulin promoter (RIP), specifically in the   -cells of 
the islets of Langerhans, and LCMV itself was used as
a trigger  [27, 28] . However, the success of this model
depended on the thymic expression of the transgene.
LCMV-NP was found to be expressed in the thymus with 
the result that high-affinity NP-specific CD8 T cells were 
deleted in the thymus and T1D development was rather 
slow (1–6 months) and required CD4 T cell help. In con-
trast, LCMV infection of RIP-LCMV-GP mice resulted 
in the rapid (10–14 days) development of T1D in a CD4 T 
cell-independent manner  [29] . The frequency of autore-
active T cells plays a central part in the development
of autoimmune diseases. Interestingly, sequential infec-
tions by heterologous viruses influence such frequencies 
massively  [30] . It has been shown that molecular mimicry 
between heterologous viruses that share similar epitopes 
might skew the T cell repertoire in a way that results in 
an acceleration of autoimmune disease  [31] . In particular, 
infection of mice with Pichinde virus (PV) that shares a 
subdominant epitope with LCMV fails to induce T1D in 
the RIP-LCMV model because the frequency of LCMV/
PV-specific T cells is too low. In contrast, sequential in-
fection of mice with LCMV followed by PV massively ac-
celerates the autodestructive process of the pancreatic   -
cells  [31, 32] . These data indicate that in the RIP-LCMV 
model, infection with a pathogen that shares a similar, 
but not identical, epitope with a specific target in the host 
is not sufficient for the initiation of autoimmune disease, 
but can accelerate an already ongoing autoimmune de-
structive process by enhancing the number of autoreac-
tive T cells. However, such an outcome is influenced by a 
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variety of factors including the nature of the epitope, the 
strength of tolerance, the location of the target structure 
and the tropism of the pathogen.
 Intuitively, one would assume that tolerance might be 
stronger to identical structures than to structures that 
just share a certain degree of similarity. Self-reactive lym-
phocytes with high avidity are more likely to be deleted 
or functionally silenced by central and/or peripheral tol-
erance mechanisms. Thus, perfect mimicry between 
identical structures might fail in inducing autoimmunity 
because of efficient tolerance mechanisms. In contrast, 
imperfect mimicry between similar, but not identical, 
structures might on the one hand circumvent tolerance, 
but on the other hand result in the generation of lympho-
cytes with only low to intermediate avidity.
 Methods 
 The CYP2D6 model offers the possibility to evaluate the roles 
of molecular mimicry and molecular identity as inducers and/or 
accelerators of autoimmune diseases in more detail. An adenovi-
rus expressing the human CYP2D6 (Ad-2D6) is used as a trigger 
for inducing autoimmune liver damage in either wild-type FVB 
mice or in transgenic CYP2D6 mice. Wild-type mice only express 
the mouse homologues of human CYP2D6, such as Cyp2D9,
Cyp2D11, Cyp2D22 and Cyp2D26, which display up to 75% ami-
no acid sequence homology to human CYP2D6 (NCBI databank). 
Cyp2D22 has been suggested as the functional orthologue of hu-
man CYP2D6 because of a certain similarity in substrate specific-
ity  [33–35] . In contrast to wild-type mice, transgenic CYP2D6 
mice express, in addition to the mouse Cyp isoenzymes, the hu-
man CYP2D6 under its own promoter, predominantly in the liv-
er. Thus, the CYP2D6 model allows for distinguishing molecular 
mimicry (Ad-2D6 infection of wild-type mice) from molecular 
identity (Ad-2D6 infection of CYP2D6 mice).
 Results 
 The CYP2D6 Mouse Model for AIH 
 First, we infected wild-type FVB mice with Ad-2D6 to 
break self-tolerance to the mouse CYP2D6 homologues. 
Within days after infection, the mice had features of 
acute liver damage such as transiently elevated serum 
aminotransferases and focal infiltrations. However, these 
features occurred in Ad-2D6-infected mice as well as in 
mice infected with a control adenovirus expressing the 
green fluorescent protein (Ad-GFP)  [36] . In contrast, at 
later times only Ad-2D6-infected mice displayed persis-
tent features characteristic for liver damage associated 
with AIH. These features included massive hepatic fibro-
sis, ‘fused’ liver lobules, disorganized architecture, cel-
lular infiltrations and focal to confluent necrosis  [36] .
Interestingly, the severity of liver damage was reduced 
and the onset of disease was delayed in Ad-2D6-infected 
transgenic CYP2D6 mice. These data indicate that mice 
expressing the human CYP2D6 in the liver established a 
certain degree of tolerance or ignorance to the challenge 
with the identical triggering molecule when compared to 
wild-type mice that only express the similar mouse Cyp 
isoenzymes.
 Fibrosis 
 The development of hepatic fibrosis was restricted to 
Ad-2D6-infected mice and was found predominantly in 
the subcapsular area, resulting in the fusion of individu-
al lobules  [36] . After 4–8 weeks of Ad-2D6 infection, peri-
portal fibrosis became apparent, which correlated with 
cellular infiltration and overall liver damage, and was 
similar to carbon tetrachloride (CCl 4 )-induced fibrosis in 
control mice at weeks 2–4 [Hintermann and Christen, 
manuscript in preparation]. However, subcapsular fibro-
sis was less frequent in CCl 4 -treated mice. Staining for 
  -smooth muscle actin revealed activation of hepatic 
stellate cells in tissue sections of both CCl 4 -treated and 
virus-infected CYP2D6 mice. Furthermore, isolation of 
hepatic stellate cells revealed an enhanced activation sta-
tus in CCl 4 -treated mice and virus-infected CYP2D6 
mice [Hintermann and Christen, manuscript in prepara-
tion]. Our data indicate that virus-infected CYP2D6 mice 
display subcapsular and periportal fibrosis, and hepatic 
stellate cell-activation similar to CCl 4 -treated animals. 
An overview of the morphological features as well as cel-
lular infiltration and fibrosis is shown in  figure 1 .
 B Cell Response 
 All Ad-2D6-infected mice generated high titers of an-
ti-CYP2D6 antibodies. The enhanced tolerance to hu-
man CYP2D6 and its mouse homologues in CYP2D6 
mice seemed to have only a minor effect on the gen-
eration of CYP2D6-specififc antibodies since the anti-
CYP2D6 antibodies reached very high levels in both
CYP2D6 as well as wild-type FVB mice  [36] . Antibody 
formation was only moderately reduced in transgenic 
CYP2D6 mice compared to wild-type FVB mice. In con-
trast, mice infected with a control adenovirus neither
developed liver damage nor generated anti-CYP2D6
antibodies. Epitope mapping revealed that such anti-
CYP2D6 antibodies predominantly recognized the iden-
tical immunodominant linear epitope WDPAQPPRD 
that is also recognized by LKM-1 antibodies from AIH 
type 2 patients  [8, 10, 14, 15, 36] . Importantly, anti-
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Acute phase (antiviral response) – week 1
Chronic phase (progressive autoimmune damage) – week 8
Morphology Infiltration HSC activation Fibrosis
a b c d
e f g h
 Fig. 1. Acute and chronic phases of Ad-2D6-induced AIH in the 
CYP2D6 mouse model. In the acute phase directly after Ad-2D6 
infection, the liver still maintains a normal morphology ( a ), but 
small focal infiltrations are visible (H&E staining of a 5-  m liver 
section,  b ). Isolated hepatic stellate cells have a naïve phenotype 
(Oil red O staining of cultured hepatic stellate cells,  c ) and no sig-
nificant subcapsular fibrosis is detectable (Sirius red staining of a 
5-  m liver section,  d ). In the chronic phase of autoimmune liver 
damage, the morphology of the liver changes and individual lobes 
become fused ( e ). Large clusters of infiltrating cells become ap-
parent predominantly in the perivascular region (H&E staining 
of a 5-  m liver section,  f ). Isolated hepatic stellate cells are acti-
vated and express   -smooth muscle actin [anti-  -smooth muscle 
actin antibody (red) and DAPI (blue) staining,  g ] and extensive 
subcapsular and perivascular fibrosis are found (Sirius red stain-
ing of a 5-  m liver section,  h ) ( [36] ; Hintermann and Christen, 
manuscript in preparation). Color in online version only. 
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 Fig. 2. Schematic overview on the development of AIH in the
CYP2D6 model. The antiviral phase includes acute inflamma-
tion, transient elevation of serum aminotransferases, cytokine 
and chemokine release, focal infiltration, and initial activation of 
hepatic stellate cells (HSC). The chronic progressive autoimmune 
phase is characterized by high titer anti-CYP2D6 antibodies,
CYP2D6-specific CD4 and CD8 T cells, strong hepatic infiltra-
tion and extensive fibrosis. The degree and onset of liver damage 
is dependent on the degree of immunologic tolerance that is more 
efficiently broken in conditions of molecular mimicry than iden-
tity ( [36] ; Hintermann and Christen, manuscript in preparation; 
Holdener and Christen, manuscript in preparation). 
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CYP2D6 antibodies generated in CYP2D6 and wild-
type FVB mice both reacted to the same major B cell 
 epitope WDPAQPPRD. These data indicate that B cell 
tolerance induction does not account for the observed 
differences in disease kinetics and severity between wild-
type and transgenic mice.
 T Cell Response 
 We analyzed the T cell-mediated immune response by 
stimulating lymphocytes with 61 overlapping 20-mer 
peptides covering the entire human CYP2D6. T cells pro-
duced interferon-  after stimulation with peptides only 
if isolated from Ad-2D6-infected mice. The frequency of 
CYP2D6-specific T cells was more than three times high-
er in lymphocytes isolated from the liver than from the 
spleen, indicating either an organ-specific proliferation 
or a selective retention process in the liver [Holdener and 
Christen, manuscript in preparation]. Importantly, the 
frequency of CYP2D6-specific CD4 as well as CD8 cells 
was dramatically decreased in transgenic CYP2D6 mice, 
indicating the presence of a strong T cell tolerance to hu-
man CYP2D6 established in transgenic CYP2D6 ex-
pressing the identical target antigen compared to wild-
type FVB mice expressing the mouse homologues only 
[Holdener and Christen, manuscript in preparation]. T 
cell epitope mapping further revealed that CYP2D6-spe-
cific T cells reacted to human CYP2D6 peptides with in-
termediate homology to the mouse homologues, but not 
to those with high homology or identity. Our data indi-
cate that molecular mimicry rather than molecular iden-
tity breaks tolerance on both the B cell and T cell level, 
subsequently causing severe and persistent autoimmune 
liver damage.
 Conclusion 
 In summary, the CYP2D6 mouse model for AIH uses 
a true human autoantigen, which seems to be important 
for establishing a chronic model that comes close to the 
immunopathogenesis of autoimmune liver disease as ob-
served in patients with AIH.  Figure 2 shows a schematic 
overview of the observed liver damage over time after in-
fection. After an initial antiviral immune response, which 
lasts for 1–2 weeks, chronic AIH develops over the follow-
ing weeks and months.
 Mechanistically, the CYP2D6 model revealed that tol-
erance is sturdier in mice expressing an autoantigen (i.e. 
human CYP2D6) that is identical to the environmental 
trigger (i.e. human CYP2D6 expressed by an infecting 
adenovirus) than in mice that only express similar auto-
antigens (i.e. the mouse Cyp isoenzymes). In particular, 
the condition of molecular mimicry was more effective 
in breaking T cell tolerance since almost no T cell reactiv-
ity to human CYP2D6 was found in Ad-2D6-infected 
CYP2D6 mice. In contrast, B cell tolerance collapsed in 
both wild-type and transgenic mice. The data confirm 
earlier studies indicating that B cell tolerance is not as 
robust as T cell tolerance  [37] . The CYP2D6 model pro-
vides a platform for investigating mechanisms involved 
in the immunopathogenesis of autoimmune-mediated 
chronic hepatic injury as seen in human AIH and evalu-
ating possible ways of therapeutic interference.
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